Selecta raises "opportunistic" financing for nanoparticle vaccine development
This article was originally published in Scrip
Executive Summary
Selecta Biosciences has raised $15 million in an "opportunistic" series C financing. OrbiMed Advisors led the round, with existing investors Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments also participating.